Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Safety, Tolerability and Pharmacokinetic Study of NOV-1776 Compared to Ketorolac Tromethamine IV in Adult Healthy Volunteers and Gout Patients

NCT06273813 is registered in ClinicalTrials.gov with Novilla Pharmaceuticals as lead sponsor.

NCT NCT06273813
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06273813 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Safety, Tolerability and Pharmacokinetic Study of NOV-1776 Compared to Ketorolac Tromethamine IV in Adult Healthy Volunteers and Gout Patients
Lead sponsor
Novilla Pharmaceuticals
Phase
Phase 1
Overall status
Unknown status
Start date
February 29, 2024
Completion date
December 31, 2024
Enrollment
30 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute gouty arthritis, acute pain, gout flare